氟伏沙明与乌干达COVID-19住院患者死亡率和症状缓解的关联:一项前瞻性干预性开放标签队列研究
该前瞻性干预性开放标签队列研究纳入316例实验室确诊的COVID-19住院患者,其中94例在标准治疗基础上接受氟伏沙明。氟伏沙明使用与死亡率降低(AHR=0.32,95%CI=0.19-0.53,p<0.001,NNT=4.46)和完全症状缓解增加(AOR=2.56,95%CI=1.53-5.51,p<0.001,NNT=4.44)显著相关,敏感性分析结果相似。
要点
- 氟伏沙明与COVID-19住院患者死亡率降低显著相关(AHR=0.32,NNT=4.46)。
- 氟伏沙明与完全症状缓解增加显著相关(AOR=2.56,NNT=4.44)。
研究设计与样本
- 前瞻性干预性开放标签队列研究,纳入316例实验室确诊的COVID-19住院患者,其中94例接受氟伏沙明联合标准治疗。
主要发现
- 氟伏沙明使用与死亡率降低显著相关(AHR=0.32,95%CI=0.19-0.53,p<0.001,NNT=4.46)。
- 氟伏沙明使用与完全症状缓解增加显著相关(AOR=2.56,95%CI=1.53-5.51,p<0.001,NNT=4.44)。
- 在161例幸存者中,氟伏沙明与出院时间无显著关联(AHR=0.81,95%CI=0.54-1.23,p=0.32)。
- 氟伏沙明组副作用有增加趋势(7.45% vs 3.15%;SMD=0.21;χ2=3.46,p=0.06),多为轻或中度,无严重副作用。
关键数值与推荐
- 主要结局为全因死亡率,次要结局为出院和完全症状缓解。
临床怎么用
- 在资源有限地区,氟伏沙明或可作为COVID-19住院患者的辅助治疗选项,但需权衡副作用并等待大规模随机试验确认。
局限性
- 本研究为开放标签非随机设计,样本量有限,结果需大规模随机试验确认,尤其在中低收入国家。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prior research suggests that fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) used for the treatment of obsessive-compulsive disorder and major depressive disorder, could be repurposed against COVID-19. We undertook a prospective interventional open-label cohort study to evaluate the efficacy and tolerability of fluvoxamine among inpatients with laboratory-confirmed COVID-19 in Uganda. The main outcome was all-cause mortality. Secondary outcomes were hospital discharge and complete symptom resolution. We included 316 patients, of whom 94 received fluvoxamine in addition to standard care [median age, 60 years (IQR = 37.0); women, 52.2%]. Fluvoxamine use was significantly associated with reduced mortality [AHR = 0.32; 95% CI = 0.19-0.53; p < 0.001, NNT = 4.46] and with increased complete symptom resolution [AOR = 2.56; 95% CI = 1.53-5.51; p < 0.001, NNT = 4.44]. Sensitivity analyses yielded similar results. These effects did not significantly differ by clinical characteristic, including vaccination status. Among the 161 survivors, fluvoxamine was not significantly associated with time to hospital discharge [AHR 0.81, 95% CI (0.54-1.23), p = 0.32]. There was a trend toward greater side effects with fluvoxamine (7.45% versus 3.15%; SMD = 0.21; χ2 = 3.46, p = 0.06), most of which were light or mild in severity and none of which were serious. One hundred mg of fluvoxamine prescribed twice daily for 10 days was well tolerated and significantly associated with reduced mortality and with increased complete symptom resolution, without a significant increase in time to hospital discharge, among inpatients with COVID-19. Large-scale randomized trials are urgently needed to confirm these findings, especially for low- and middle-income countries, where access to vaccines and approved treatments against COVID-19 is limited.
引用
- Kirenga BJ, Mugenyi L, Sánchez-Rico M, et al. Association of fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 in Uganda: a prospective interventional open-label cohort study. Mol Psychiatry. 2023. PMID: 36869228. doi:10.1038/s41380-023-02004-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。